论文部分内容阅读
目的分析人乳腺组织中P-JNK和beclin 1的表达变化,探讨二者在乳腺癌鉴别诊断及治疗中的临床作用。方法应用免疫组化SP法检测20例乳腺正常上皮、30例乳腺导管原位癌和70例乳腺浸润性导管癌中P-JNK和beclin 1蛋白的阳性率,Western blot检测乳腺浸润性导管癌及正常乳腺组织中P-JNK和beclin 1蛋白的表达量。结果 1在正常乳腺组织、乳腺导管原位癌和乳腺浸润性导管癌中P-JNK阳性率分别为80%、43.3%和18.6%,beclin 1阳性率为85%、46.7%和24.1%。2乳腺癌中二者阳性率与组织学分级相关(P<0.05),与患者临床分期、淋巴结转移、ER和PR阳性率无关(P均>0.05)。370例乳腺癌组织中,P-JNK和beclin 1表达呈正相关性(P<0.01)。4Western blot结果表明,P-JNK和beclin 1蛋白在乳腺癌组织中蛋白表达量低于二者在乳腺正常组织中的蛋白表达量(P<0.05)。结论在乳腺癌中P-JNK和beclin 1均低表达,P-JNK和beclin 1具有正相关性,二者可能在乳腺癌发生、发展过程中受到抑制,因此推断联合检测P-JNK和beclin对于乳腺良、恶性病变的鉴别以及对乳腺癌的治疗、评价预后有重要参考价值。
Objective To analyze the expression changes of P-JNK and beclin 1 in human breast tissues and to explore their clinical roles in the differential diagnosis and treatment of breast cancer. Methods The positive rates of P-JNK and beclin 1 protein in 20 cases of breast normal epithelium, 30 cases of ductal carcinoma in situ and 70 cases of invasive ductal carcinoma of the breast were detected by immunohistochemical SP method. The invasive ductal carcinoma of breast and The expression of P-JNK and beclin 1 protein in normal breast tissue. Results 1 The positive rates of P-JNK in normal breast tissue, ductal carcinoma in situ and breast invasive ductal carcinoma were 80%, 43.3% and 18.6%, respectively. The positive rates of beclin 1 were 85%, 46.7% and 24.1% respectively. 2 breast cancer (P <0.05), but not with the clinical stage, lymph node metastasis, positive rate of ER and PR (all P> 0.05). In 370 cases of breast cancer, the expression of P-JNK and beclin 1 were positively correlated (P <0.01). 4 Western blot results showed that the protein expression of P-JNK and beclin 1 in breast cancer tissues was lower than that in normal breast tissues (P <0.05). Conclusions Both P-JNK and beclin 1 are down-regulated in breast cancer. P-JNK and beclin 1 have a positive correlation, both of which may be inhibited during the development of breast cancer. Therefore, it is concluded that the combination of P-JNK and beclin Breast benign and malignant lesions as well as the treatment of breast cancer, the prognosis of an important reference value.